Aligos Therapeutics, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On September 10, 2026, Aligos Therapeutics (market cap ~$19.9M) entered into a material definitive agreement reported under Item 1.01 of Form 8-K filed September 15, 2026. The filing provides no concrete details: no counterparty name, dollar amounts, share counts, percentages, or terms are disclosed in the accessible text. The agreement's nature, scope, and financial impact cannot be determined from this filing.
Why this rating
Material agreement filing is procedurally required but lacks substance; actual impact unknowable without full disclosure document or exhibit. At $19.9M market cap, even modest deals matter, but cannot assess magnitude without data.
Extracted items
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.